Citi Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Bristol-Myers Squibb (BMY) Pressured on Market Open, Down 6.6%
October 22, 2018 9:31 AM EDTBristol-Myers Squibb (NYSE: BMY) Pressured on Market Open, Down 6.6%
... MoreBristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -067 Clinical Trial for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)
October 22, 2018 6:00 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial the longest follow-up to date which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 months,... More
